BCL6

Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, February 27, 2024
CDK4, ESPP, Research, BCL6, Sale, Exercise, LRRK2, ARVN, CDK7, ATM, HER2, Genentech, European Medicines Agency, Congress, Development, Breast cancer, Pfizer, CBR, ESMO, Everolimus, Greyhawk, ESR1, Oncology, Enrollment, Investment, Insurance, Prostate cancer, PFS, Food, Ribociclib, Bayer, Administration, Patient, Neutropenia, Pharmaceutical industry

NEW HAVEN, Conn., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • Median PFS of 11.1 and 11.0 months in patients with ESR1 wild-type and ESR1 mutant tumors, respectively.
  • Announced the appointment of Randy Teel, Ph.D., Arvinas’ current senior vice president of corporate and business development, to the role of interim chief financial officer and treasurer.
  • The Arvinas Board of Directors has launched a formal search process to identify Mr. Cassidy’s permanent replacement.
  • Revenues: Revenue was $78.5 million and $(43.1) million for the year and quarter ended December 31, 2023 as compared with $131.4 million and $38.0 million for the year and quarter ended December 31, 2022.

Long-Term Data for Kite’s Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma

Retrieved on: 
Monday, December 11, 2023
Oncology, Health, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, BCL2, Fever, MYC, Progression-free survival, ASH, Aes, CRS, EFS, B-cell lymphoma, Headache, Cytopenia, Non-Hodgkin lymphoma, Patient, Abstract, PFS, DOR, BCL6, Histology, ORR, MD, Survival, Doctor of Philosophy, Drug, Society, OS, Confidence interval, Axicabtagene ciloleucel, SVP, Cytokine release syndrome, Pharmaceutical industry

“Patients with high-risk, large B-cell lymphoma, have a poor prognosis with currently available therapies,” said Julio C. Chavez, MD, lead investigator, Moffitt Cancer Center.

Key Points: 
  • “Patients with high-risk, large B-cell lymphoma, have a poor prognosis with currently available therapies,” said Julio C. Chavez, MD, lead investigator, Moffitt Cancer Center.
  • “This is particularly true of patients with double- or triple-hit histology, who have a median survival of under a year with standard treatment.
  • Prolonged cytopenias of any grade (present Day ≥30 post-infusion) occurred in 9 patients (n=7 neutrophil count decreased) and were resolved by data cutoff.
  • Among treated patients, the in vivo Yescarta expansion and persistence profiles are consistent with previous observations.

Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 7, 2023
Research, Sale, Arm, Equity method, Bayer, ATM, ESMO, LRRK2, RPF, Enrollment, Greyhawk, Income tax, CTA, Prostate cancer, Exercise, Development, PROTAC, Pfizer, Clinical trial, BCL6, Neuroscience, CDK4, Breast cancer, State Administrative Expenses, ARVN, Genentech, European Society of Gynaecological Oncology, Investment, AR, Patient, Administration, Everolimus, Pharmaceutical industry, Medical imaging, Dietary supplement, Life insurance, IND, Gaius Papirius Carbo Arvina

NEW HAVEN, Conn., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • Research and Development Expenses: Research and development expenses were $85.9 million for the quarter ended September 30, 2023, as compared with $77.5 million for the quarter ended September 30, 2022.
  • General and Administrative Expenses: General and administrative expenses were $22.6 million for the quarter ended September 30, 2023, as compared with $20.0 million for the quarter ended September 30, 2022.
  • Revenues: Revenues were $34.6 million for the quarter ended September 30, 2023, as compared with $33.2 million for the quarter ended September 30, 2022.
  • Net Loss: Net loss was $64.0 million for the quarter ended September 30, 2023, as compared with $66.2 million for the quarter ended September 30, 2022.

Cellectar Biosciences Reports Complete Response in a Relapsed/Refractory CNS Lymphoma Patient

Retrieved on: 
Tuesday, February 28, 2023
Female, BCL6, PCNSL, Cancer, Lymphoma, Survival, Primary central nervous system lymphoma, Pharmacotherapy, Patient, CT, CNS, Neoplasm, Recombinant DNA, Medical imaging

She had BCL6 gene rearrangement which predicts worse outcomes and reduced survival.

Key Points: 
  • She had BCL6 gene rearrangement which predicts worse outcomes and reduced survival.
  • 50 days post cycle 1 day 1 infusion, a CT scan showed a very good partial response (VGPR) with a 93% reduction in tumor volume.
  • “Complete resolution of this patient’s primary CNS lymphoma, which had been relapsed or refractory to four lines of therapy, is extraordinary and provides further evidence of iopofosine’s ability to cross the blood/brain barrier and target cancer.
  • Importantly, these patients currently have very poor prognoses and there is no approved therapy for CNS lymphoma,” said Dr. Andrei Shustov, senior vice president, medical of Cellectar.

Biomea Fusion Announces Upcoming Presentations of Preclinical Data in Diffuse Large B-Cell Lymphoma, Multiple Myeloma, and Several KRAS Mutant Solid Tumors for BMF-219 at AACR Annual Meeting 2022

Retrieved on: 
Tuesday, March 8, 2022
BCL2, DHL, MYC, RNA-Seq, DLBCL, Securities Act of 1933, Risk, Â, Kirsten, RAS, Illumina, Growth, MAX, NSCLC, Drug Quality and Security Act, Lists of diseases, Colorectal cancer, Diabetes, BCL6, KRAS, Acute leukemia, Securities Exchange Act of 1934, GLOBE, Patient, Cancer, HOXA9, Neoplasm, SEC, American Association for Cancer Research, Ernest, NRAS, IND, Research, DEL, Osteopathic medicine in Canada, Gene expression, 2021 Essex County Council election, Chromosomal translocation, B-cell lymphoma, Association, NPM1, IC50, Nasdaq, AACR, Multiple myeloma, THL, Oncogene, Abstract, Board, American Association, Gene, Pancreatic cancer, CRC, Vaccine, Pharmaceutical industry, Fine chemical

The AACR Annual Meeting will be held from April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, LA.

Key Points: 
  • The AACR Annual Meeting will be held from April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, LA.
  • In preclinical models, BMF-219 demonstrated near complete tumor growth inhibition in both MYC-dependent and pan-KRAS mutant cancers.
  • These mutations are broadly manifested in numerous tumor types and are generally considered categories of very high unmet need.
  • Biomea Fusion explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Cicero Diagnostics reaches 10,000-patient milestone with its ReceptivaDx™ Test

Retrieved on: 
Thursday, October 14, 2021
Health, Medical Devices, Other Health, Live birth, BCL6, Endometriosis, Reproductive medicine, Growth, Hormone, Infertility, Cicero, Inflammation, Patient, Failure, Society, IVF, American Society for Reproductive Medicine, Research, Female, Medical device, Pharmaceutical industry

Womens healthcare company, Cicero Diagnostics Inc., offering ReceptivaDx for unexplained infertility, implantation failure and recurrent pregnancy loss, today announced it has reached the 10,000-patient mark from fertility centers using ReceptivaDx and its signature BCL6 marker.

Key Points: 
  • Womens healthcare company, Cicero Diagnostics Inc., offering ReceptivaDx for unexplained infertility, implantation failure and recurrent pregnancy loss, today announced it has reached the 10,000-patient mark from fertility centers using ReceptivaDx and its signature BCL6 marker.
  • The milestone signifies substantial test growth since the companys inception and reflects the role ReceptivaDx now plays as a new standard of care in fertility centers helping patients who have experienced IVF failure.
  • Today ReceptivaDx is used by more than 350 fertility centers around the country and has been introduced in several strategic international markets with more expected, said Chris Jackson, CEO Cicero Diagnostics.
  • Cicero Diagnostics is the exclusive licensed provider of the BCL6 test for the detection of uterine lining dysfunction commonly associated with endometriosis.

Cicero Diagnostics to Partner with Mediaplanet a Second Time in a Campaign to Educate Women Contemplating IVF About its ReceptivaDX Test

Retrieved on: 
Thursday, September 16, 2021
Endometriosis, Education, IOS, CEO, Health, Infertility, Cicero, Patient, Female, IVF, Physician, Fertility, Android, BCL6, Partnership, Goal, Research, Woman, Medical device

The IVF guide marks the second engagement between Cicero Diagnostics and Mediaplanet.

Key Points: 
  • The IVF guide marks the second engagement between Cicero Diagnostics and Mediaplanet.
  • In March 2021, the partnership created the Future of Fertility campaign aimed at reducing and removing the stigma around infertility.
  • Recent outcomes data shows that IVF transfer success rates move from just 12% to 64% on the next IVF transfer when BCL6-positivity is treated.
  • The app is an informational and educational tool designed to support women and physicians through their experience with the ReceptivaDx test.